VEGFA and neoplasm: Further analyses were undertaken in order to investigate potential correlations between percent reduction in tumour perfusion and clinical benefit, duration of therapy, percent reduction in FDG-SUV, plasma levels of sunitinib and SU12662, and changes in plasma levels of VEGF and sVEGFR-2 (Table 2, Figures 4 and 5).